drug · antibody
odronextamab
Phase 3updated 3mo agoby $REGN REGENERON PHARMACEUTICALS, INC.🔗 ChEMBL
Phase 3community read0 votes
Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and follicular lymphoma and 3 investigational indications.
indications
indications
DLBCL
targets
B-lymphocyte antigen CD20T cell surface glycoprotein CD3
all catalysts(0)
nothing on the calendar yet
Trials studying odronextamab
- phase3A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
- phase1Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
- phase1A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies
- phase1A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
- phase3A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
- phase3A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma
- phase2Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
- phase2Odronextamab in Low Tumor Volume Advanced FL
News(1)
- Scholar Rock ditches Novo’s legacy Catalent plant in FDA refiling of SMA drugScholar Rock has dropped Novo Nordisk’s troubled Catalent facility as a contract manufacturer in its FDA refiling for apitegromab, a spinal muscular atrophy candidate, after a recent inspection of…fiercebiotech · 10d ago
Data sources
last refreshed 42m ago
Found something off?
comments(0)
5-min edit window · permanent after that